niacinamide has been researched along with vorinostat in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hruby, H; Jung, M; Meier, R; Neugebauer, RC; Sippl, W; Uchiechowska, U; Valkov, V; Verdin, E | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Forgione, M; Hailu, GS; Mai, A; Robaa, D; Rotili, D; Sippl, W | 1 |
| Agbaba, D; Bertrand, P; Blanquart, C; Bouchet, S; Fouchaq, B; Linot, C; Nikolic, K; Roche, J; Ruzic, D | 1 |
| McFarlane, M; Preston, CM | 1 |
| Cassell, M; Lindsay, DS; Mitchell, SM; Reilly, CM; Strobl, JS | 1 |
| Dai, Y; Dasmahapatra, G; Dent, P; Grant, S; Yerram, N | 1 |
| Curiel, DT; Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Lee, R; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Roberts, JD; Yacoub, A; Zhang, G | 1 |
| Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Hylemon, PB; Liu, X; Martin, AP; Mitchell, C; Norris, J; Park, MA; Rahmani, M; Ryan, K; Spiegel, S; Zhang, G | 1 |
| Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A | 1 |
| Allegood, J; Dent, P; Fisher, PB; Grant, S; Häussinger, D; Larner, A; Mitchell, C; Ogretmen, B; Park, MA; Reinehr, R; Spiegel, S; Voelkel-Johnson, C; Yacoub, A; Zhang, G | 1 |
| Dent, P; Grant, S; Häussinger, D; Ogretmen, B; Park, MA; Reinehr, R; Voelkel-Johnson, C; Yacoub, A | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD | 1 |
| Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S | 1 |
| Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE | 1 |
| Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H | 1 |
| Blay, JY; Dumont, AG; Dumont, SN; Reynoso, D; Trent, JC; Yang, D | 1 |
| Angara, B; Arditi, M; Bhowmick, NA; Dru, C; Duong, F; Fernandez, A; Haldar, S; Mishra, R; Tripathi, M | 1 |
| Gülow, K; Kießling, MK; Klemke, CD; Krammer, PH; Nicolay, JP; Schlör, T; Süss, D | 1 |
2 review(s) available for niacinamide and vorinostat
| Article | Year |
|---|---|
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Topics: Animals; Antiparasitic Agents; Drug Repositioning; Helminth Proteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leishmania; Plasmodium; Protozoan Proteins; Schistosoma; Toxoplasma; Trypanosoma | 2017 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
1 trial(s) available for niacinamide and vorinostat
| Article | Year |
|---|---|
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2013 |
17 other study(ies) available for niacinamide and vorinostat
| Article | Year |
|---|---|
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode.
Topics: Acetylation; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Databases, Factual; Drug Screening Assays, Antitumor; Humans; Hydrogen Bonding; Models, Molecular; Naphthalenes; Protein Binding; Pyrones; Recombinant Proteins; Sirtuin 2; Sirtuins; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Tubulin | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
Topics: | 2019 |
Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16.
Topics: Acetamides; Animals; Cell Differentiation; DNA Damage; Genes, Immediate-Early; Genes, Viral; Genetic Complementation Test; Herpes Simplex Virus Protein Vmw65; Herpesvirus 1, Human; Hydroxamic Acids; Mice; Mutation; Niacinamide; Promoter Regions, Genetic; Tumor Cells, Cultured; Virus Replication; Vorinostat | 1998 |
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Topics: Animals; Antiprotozoal Agents; Butyrates; Cattle; Cell Line; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxylamines; Inhibitory Concentration 50; Niacinamide; Parasitic Sensitivity Tests; Phenylbutyrates; Quinolines; Toxoplasma; Valproic Acid; Vitamin B Complex; Vorinostat | 2007 |
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Topics: Benzenesulfonates; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Tumor Cells, Cultured; Vorinostat | 2007 |
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2008 |
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Caspase 8; Cell Survival; Ceramides; eIF-2 Kinase; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; fas Receptor; Humans; Hydroxamic Acids; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vorinostat | 2008 |
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Hydroxamic Acids; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Niacinamide; Oxidoreductases; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2009 |
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Ester Hydrolases; Cell Line, Tumor; Ceramides; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Vorinostat | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Fas Ligand Protein; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Phosphotyrosine; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sorafenib; src-Family Kinases; Vorinostat | 2010 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat | 2012 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Transfection; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
Topics: Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Doxorubicin; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Sarcoma, Small Cell; Sorafenib; Vorinostat | 2014 |
Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis.
Topics: Acrolein; Animals; Cells, Cultured; Cyclophosphamide; Cystitis; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Glycosylases; DNA Methyltransferase 3B; DNA Repair; Down-Regulation; Female; Histone Deacetylase Inhibitors; Hydroxamic Acids; Mesna; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Smooth Muscle; Niacinamide; Reactive Oxygen Species; Urinary Bladder; Vorinostat | 2016 |
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2017 |